Therapy Areas: Devices
Clovis Oncology Names Azelby, Fair to Board of Directors
12 October 2018 - - US-based biopharmaceutical company Clovis Oncology, Inc. (NASDAQ: CLVS) has appointed Robert W. Azelby and Richard A. Fair to the company's board of directors, the company said.

Robert W. Azelby has served as the president and chief executive officer, and a member of the board of directors, of Alder BioPharmaceuticals, Inc. since June 2018.

From November 2015 to May 2018, Azelby served as executive vice president, chief commercial officer of Juno Therapeutics, Inc. From June 2012 to October 2015, Azelby served as vice president and general manager, oncology at Amgen Inc.

From October 2010 to May 2012, he served as Amgen's vice president, Amgen Oncology Sales.

Prior to that, he served in various positions at Amgen, including periods as vice president, commercial effectiveness unit and general manager of Amgen Netherlands.

Azelby previously served on the board of directors of Cascadian Therapeutics, Inc. Azelby holds a B.A. in Economics and Religious Studies from the University of Virginia and an M.B.A. from Harvard Business School.

The company believes Azelby possesses specific attributes that qualify him to serve as a member of the company's board of directors, including his years of leadership and commercial experience in the oncology industry.

Richard A. Fair has served as president and chief executive officer, and a member of the board of directors, of Bellicum Pharmaceuticals, Inc. since January 2017.

Prior to joining Bellicum, Fair served as senior vice president, Therapeutic Head Oncology Global Product Strategy at Genentech, Inc., a subsidiary of Roche Holding AG.

From April 2006 to January 2014, Fair held other positions at Genentech, including vice president, global product strategy hematology and signaling, from November 2012 through December 2013, and vice president, sales and marketing, Oral Oncolytics, from May 2010 to November 2012.

Prior to Genentech, Fair held positions at Johnson and Johnson, a pharmaceutical and medical device company. Fair received his B.S. in computer science from the University of Michigan and his MBA from Columbia University.

The company believes Fair possesses specific attributes that qualify him to serve as a member of the company's board of directors, including his years of leadership and commercial experience in the oncology industry.

Clovis Oncology is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the US, Europe and additional international markets.

The company targets development programs at specific subsets of cancer populations, and simultaneously develops, with partners, diagnostic tools that direct a compound in development to the population that is most likely to benefit from its use.

Clovis Oncology is headquartered in Boulder, Colorado, and has additional offices in San Francisco and Oakland, California and Cambridge, UK.
Login
Username:

Password: